Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma

NCT00161590 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

T-Cell Lymphoma
Lymphoma, Non-Hodgkin's

Interventions

DRUG: CHOP and alemtuzumab

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]